Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385092 | 0.77 | HRH4 (0.61) | HRH4HTR3AHTR6HRH3CYP1A2 | |
| SCHEMBL2382066 | 0.77 | HRH4 (0.57) | HRH4HTR3AHTR6CYP1A2ALOX15 | |
| SCHEMBL4054378 | 0.75 | CYP1A2 (0.62) | HRH4HRH3CYP1A2ALOX15CYP2C19 | |
| SCHEMBL2387088 | 0.75 | HRH4 (0.61) | HRH4HTR3ACYP1A2ALOX15CYP2C19 | |
| SCHEMBL2386830 | 0.75 | HRH4 (0.61) | HRH4HTR3AHTR6HRH3CYP1A2 | |
| SCHEMBL2386699 | 0.72 | HRH4 (1.00) | HRH4HTR3AHTR6HRH3CYP1A2 | |
| SCHEMBL2385679 | 0.72 | HRH4 (0.61) | HRH4HTR3AHTR6HRH3CYP1A2 | |
| SCHEMBL2386813 | 0.72 | HRH4 (0.73) | HRH4HTR3AHTR6HRH3CYP1A2 | |
| SCHEMBL2383430 | 0.71 | HRH4 (0.53) | HRH4HTR3AHTR6CYP1A2CYP2C19 | |
| SCHEMBL2385659 | 0.70 | HRH4 (0.56) | HRH4HTR3AHTR6CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | claimed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | claimed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| US-8022209-B2 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-20 | — | — | US | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | HRH4 1/4885HTR3A 14/4885HTR6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.